Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma.

@article{Micallef2011EpratuzumabWR,
  title={Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma.},
  author={Ivana N M Micallef and Matthew J Maurer and G. A. White J. A. Vaccaro H. M. Wiseman and Daniel A. Nikcevich and Paul James Kurtin and Michael W. Cannon and Domingo G P{\'e}rez and Gamini S. Soori and Brian K Link and Thomas Matthew Habermann and Thomas E Witzig},
  journal={Blood},
  year={2011},
  volume={118 15},
  pages={4053-61}
}
Approximately 60% of patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) are curable with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemoimmunotherapy. Epratuzumab (E) is an unlabeled anti-CD22 monoclonal antibody with efficacy in relapsed DLBCL. This phase 2 trial tested the safety and efficacy of combining E with R-CHOP (ER-CHOP) in untreated DLBCL. A secondary aim was to assess the efficacy of interim positron emission tomography (PET) to… CONTINUE READING
48 Citations
38 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 48 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Outcome of patients with chemotherapy refractory and early progressive DLBCL after R-CHOP

  • F Hitz, J Connors, R Gascoyne
  • Blood .
  • 2010
1 Excerpt

Similar Papers

Loading similar papers…